Allied Blenders & Distillers Regulatory Approval

Allied Blenders & Distillers Business Update

ABD recorded its highest-ever monthly sales at over 3.6 million cases in October 2026. Officer's Choice Brandy and Sumo Whisky joined the millionaire club, reaching six brands.

Allied Blenders & Distillers Legal & Regulatory

Allied Blenders disclosed that the Bombay High Court appointed a Sole Arbitrator to adjudicate a dispute with former employee Mr. Alok Gupta over his employment agreement. No financial implication or quantum of claims is ascertainable at present.

Allied Blenders & Distillers Product Launch

ABD Maestro launches Rangeela Jhatpat Jamun and Kala Khatta vodka flavours. Available in Maharashtra at ₹2,500 (750ml) and ₹625 (180ml), with Goa, Haryana, and UP to follow.

Allied Blenders & Distillers Earnings Call Transcript: Key Takeaways

ABD achieved record quarterly volumes crossing 10 million cases, driven by aggressive premiumization and the turnaround of flagship brands in key Southern markets.

Call

Guides 15% growth

Allied Blenders & Distillers Investor Presentation: Key Takeaways

Q2FY27 revenue ₹1,152 Cr (+15.8%), EBITDA ₹143 Cr (+10.0%), margin 12.4% (-66 bps), PAT ₹69 Cr (+9.7%). Record 10.0 Mn case volume; premiumisation and P&A-led strategy.

Allied Blenders & Distillers Results Update

Allied Blenders reported Q2FY27 income from operations of ₹1,152 crore, up 15.8% YoY, with PAT of ₹69 crore. Record volumes and newly commissioned plants supported the growth.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.